RMD ResMed Inc.

ResMed to Report Second Quarter Fiscal 2023 Earnings on January 26, 2023

ResMed to Report Second Quarter Fiscal 2023 Earnings on January 26, 2023

SAN DIEGO, Jan. 12, 2023 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the second quarter of fiscal year 2023 on Thursday, January 26, 2023, after the New York Stock Exchange closes. Following the release, ResMed management will host a webcast to discuss the results. Other forward-looking and material information may also be discussed during the webcast.

Earnings webcast details:

  • Location:


  • Date:
Thursday, January 26, 2023
  • Time:
1:30 p.m. PDT / 4:30 p.m. EDT
  • International:
London, Thursday, January 26, 2023, 9:30 p.m. GMT
 Sydney, Friday, January 27, 2023, 8:30 a.m. AEDT

Please note: ResMed does not use outside phone lines to access the earnings call; the call is accessible via the above webcast link only.

A replay of the earnings webcast will be accessible on ResMed’s website and available approximately two hours after the webcast. In addition, a phone replay will be available approximately two hours after the webcast and will be accessible from January 26, 2023, until February 9, 2023, at:

  • U.S.: +1 877.660.6853
  • International: +1 201.612.7415
  • Conference ID: 13735371

About ResMed

At ResMed (NYSE: RMD, ASX: RMD) we pioneer innovative solutions that treat and keep people out of the hospital, empowering them to live healthier, higher-quality lives. Our digital health technologies and cloud-connected medical devices transform care for people with sleep apnea, COPD, and other chronic diseases. Our comprehensive out-of-hospital software platforms support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. By enabling better care, we improve quality of life, reduce the impact of chronic disease, and lower costs for consumers and healthcare systems in more than 140 countries. To learn more, visit and follow @ResMed.

For investorsFor media
Amy WakehamJayme Rubenstein
+1 858.836.5000+1 858.836.6798


EN
12/01/2023

Underlying

RMDResMed Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ResMed Inc.

 PRESS RELEASE
Free
RMD RESMED INC.

Obstructive Sleep Apnea Expected to Affect Nearly 77 million U.S. Adul...

Obstructive Sleep Apnea Expected to Affect Nearly 77 million U.S. Adults by 2050, New Resmed Study Finds Published in The Lancet Respiratory Medicine, research reveals sharp rise in OSA, especially among women, highlighting the need for earlier diagnosis, preventative strategies, and personalized care SAN DIEGO, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing, and care delivered in the home, today announced the publication of a landmark study in projecting a significant rise in obstructive sleep apnea (OS...

August 27, 2025 1 EN
 PRESS RELEASE
Free
RMD RESMED INC.

Resmed Strengthens Innovation Leadership with Dual Red Dot Design Awar...

Resmed Strengthens Innovation Leadership with Dual Red Dot Design Awards and 10,000 Patents and Designs Milestones underscore Resmed’s leadership and commitment to delivering life-changing health technology that people love SAN DIEGO, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing, and care delivered in the home, today announced that its  nasal cradle mask won two prestigious : Product Design 2025 in both the Innovative Products and Medical Design & Healthcare categories. The AirTouch N30i features Resmed...

August 21, 2025 1 EN
 PRESS RELEASE
Free
RMD RESMED INC.

Resmed Announces Election of Nicole Mowad-Nassar to Board of Directors...

Resmed Announces Election of Nicole Mowad-Nassar to Board of Directors and Upcoming Retirement of Rich Sulpizio Mowad-Nassar is Senior Vice President at AbbVie and President, Specialty and U.S. Therapeutics Operations Her appointment brings over 30 years of strategic, commercial, and operational expertise in the pharmaceutical and broader healthcare industry, with a focus on digital innovation SAN DIEGO, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD) today announced the election of Nicole Mowad-Nassar to its board of directors, effective August 15, 2025. The company als...

August 18, 2025 1 EN
 PRESS RELEASE
Free
RMD RESMED INC.

Resmed Inc. Announces Results for the Fourth Quarter of Fiscal Year 20...

Resmed Inc. Announces Results for the Fourth Quarter of Fiscal Year 2025 Year-over-year revenue grows 10%, operating profit up 19%, non-GAAP operating profit up 19%Operating cash flow of $539 millionQuarterly dividend increases 13% to $0.60 per share Note: A webcast of Resmed’s conference call will be available at 4:30 p.m. ET today at  SAN DIEGO, July 31, 2025 (GLOBE NEWSWIRE) -- Resmed Inc. (NYSE: RMD, ASX: RMD) today announced results for its quarter ended June 30, 2025. Fourth Quarter 2025 HighlightsAll comparisons are to the prior year period Revenue incre...

July 31, 2025 1 EN
 PRESS RELEASE
Free
RMD RESMED INC.

Resmed to Report Fourth Quarter Fiscal 2025 Earnings on July 31, 2025

Resmed to Report Fourth Quarter Fiscal 2025 Earnings on July 31, 2025 SAN DIEGO, July 01, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the fourth quarter of fiscal year 2025 on Thursday, July 31, 2025, after the New York Stock Exchange closes. Following the release, Resmed management will host a webcast to discuss the results. Other forward-looking and material information may also be discussed during the webcast. Earnings webcast details:  •Location: •Date:Thursday, July 31, 2025 •Time:1:30 p.m. PDT / ...

July 1, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch